Events – Clinical Value of Diagnostics

LEAD 2025 Session Recordings

Ronald Ho — Thu, 07 Aug 2025 05:39:34 +0000

Jointly hosted by:

Topic 1: Past, Present and Future: Advances in the Screening and Diagnosis of MAFLD

Faculty

Prof. Jacob George

The University of Sydney
Australia

Prof. Ming-Lung Yu

Kaohsiung Medical University
Taiwan

Dr. Anand Kulkarni

Asian Institute of Gastroenterology
India

Prof. Rosmawati Mohamed

National University Malaysia
Malaysia

Prof. Jing-Houng Wang

Kaohsiung Chang Gung Memorial Hospital
Taiwan

Topic 2: Evolving Tools for Advancing the Fight Against HBV and HCV

Faculty

Prof. Ashish Kumar

Sir Ganga Ram Hospital
India

Prof. Pisit Tangkijvanich

Chulalongkorn University
Thailand

Prof. Rachel Jeng

Chang Gung University
Taiwan

Topic 3: Findings of the Asia Pacific Expert Consensus: Clinical and Economic Utility of Biomarker-based Algorithms in the Early Detection and Surveillance of HCC

Faculty

Prof. Teerha Piratvisuth

The Gastroenterological Association of Thailand
Thailand

Topic 4: Emerging Evidence and Updates of Clinical Algorithms in HCC Surveillance

Faculty

Prof. Jia-Horng Kao

National Taiwan University Hospital
Taiwan

Prof. Yujuan Guan

Guangzhou Eighth People’s Hospital
China

Prof. Wah-Kheong Chan

University of Malaya
Malaysia

Prof. Ming-Ling Chang

Chang Gung Memorial Hospital
Taiwan

Prof. Teerha Piratvisuth

The Gastroenterological Association of Thailand
Thailand

Prof. Henry Chan

The Chinese University of Hong Kong
Hong Kong

Topic 5: Evolving Strategies in uHCC Care

Faculty

Prof. Yi-Hsiang Huang

Taiwan Liver Cancer Association
Taiwan

Prof. Wei-Chen Lee

Chang Gung Memorial Hospital
Taiwan

Prof. I-Cheng Lee

Taipei Veterans General Hospital
Taiwan

Prof. Kenneth Chok

The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong

This content is targeted at healthcare professionals and shall be used as a reference only. This material represents personal viewpoints and is intended to promote the communication and exchange of medical information.

This content may contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

This content may contain products or clinical indications that have not yet been registered or approved in your country. Please refer to the locally approved package insert for detailed prescription information or check with your local Roche representative.

The post LEAD 2025 Session Recordings appeared first on Clinical Value of Diagnostics.

APAC Oncology Summit 2024

Isabel Low — Mon, 06 Jan 2025 05:48:44 +0000

Supported by:

This content is targeted at healthcare professionals and shall be used as a reference only. This material represents personal viewpoints and is intended to promote the communication and exchange of medical information. This content may contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This contentl may contain products or clinical indications that have not yet been registered or approved in your country. Please refer to the locally approved package insert for detailed prescription information or check with your local Roche representative.

Speakers

Dr. Herbert Loong

Deputy Medical Director,
Phase 1 Clinical Trials Centre,
The Chinese University of Hong Kong

Dr. Linda Mileshkin

Director of Medical Oncology,
Peter MacCallum Cancer Centre, Australia

Dr. Sewanti Limaye

Director of Medical & Precision Oncology,
Reliance Foundation Hospital & Research Center, India

Dr. Dejan Juric

Director,
Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program,
Massachusetts General Hospital Cancer Centre, U.S.A.

Moderators

Dr. Daniel Chan

Senior Consultant,
Medical Oncology,
ICON Cancer Centre, Singapore

Dr. Yoon Sim Yap

Senior Consultant,
Division of Medical Oncology,
National Cancer Centre, Singapore

Agenda

Topic

Speakers

Opening and Introduction

Mr. Lance Little
Head of Region Asia Pacific,
Roche Diagnostics Ltd.

Trends and Challenges in Molecular Tumour Board Implementation in Asia-Pacific Region: APAC MTB Expert Consensus Statement

Dr. Herbert Loong

Unlocking the Power of Liquid Biopsy-based Profiling in Clinical Practice

Dr. Linda Mileshkin

Panel Discussion: Facilitating Access to Molecularly Guided Treatment Options by Leveraging Advancements in Genomic Profiling and Molecular Tumour Boards

Panelists:
Dr. Herbert Loong
Dr. Linda Mileshkin
Dr. Aya Helali

Break

All

The Evolution of Comprehensive Genomic Profiling: From Lung Cancer Pioneers to Ovarian and Breast Cancer Paradigms

Dr. Sewanti Limaye

Targeting PIK3CA Mutation in Breast Cancer: From Testing to Therapeutic Strategies

Dr. Dejan Juric

Panel Discussion: Management of Novel Genes in Breast Cancer

Panelists:
Dr. Dejan Juric
Dr. Sewanti Limaye
Dr. Pranav Dorwal

Closing

Dr. Ahmed Elhusseiny
Area Head APAC,
Roche Pharmaceuticals

This material represents personal viewpoint and is intended to promote the communication and exchange of medical information, and shall be used by healthcare professionals as a reference only. This material may contain medicinal products or clinical indications that have not yet been approved in your country. Please refer to the locally approved package insert for detailed prescription information.

The post APAC Oncology Summit 2024 appeared first on Clinical Value of Diagnostics.

Global Talks Lung Cancer Forum

Isabel Low — Mon, 22 Jul 2024 01:55:32 +0000

In this webinar, experts in lung cancer from around the globe discuss the latest advancements in lung cancer treatment. Watch the webinar recording to get updates on treatment options for resectable NSCLC, thoracic surgery, and neoadjuvant immunotherapy for NSCLC.

You are viewing an International Congress run by Roche and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of Global Talk, best efforts were undertaken by Roche to ensure compliance with the applicable law and regulations, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.

The post Global Talks Lung Cancer Forum appeared first on Clinical Value of Diagnostics.

Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer

Isabel Low — Wed, 26 Jun 2024 12:16:11 +0000

...

The post Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer appeared first on Clinical Value of Diagnostics.

Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready?

Isabel Low — Wed, 26 Jun 2024 12:07:07 +0000

...

The post Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready? appeared first on Clinical Value of Diagnostics.

Overview of the Current Cervical Cancer Screening Landscape in Singapore

Isabel Low — Wed, 26 Jun 2024 11:46:02 +0000

...

The post Overview of the Current Cervical Cancer Screening Landscape in Singapore appeared first on Clinical Value of Diagnostics.

Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies

Isabel Low — Fri, 31 May 2024 03:13:01 +0000

...

The post Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies appeared first on Clinical Value of Diagnostics.

Management of early-stage NSCLC with driver mutations

Isabel Low — Fri, 31 May 2024 03:00:32 +0000

...

The post Management of early-stage NSCLC with driver mutations appeared first on Clinical Value of Diagnostics.

21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy

Isabel Low — Tue, 14 May 2024 02:03:05 +0000

While cervical cancer is preventable, an estimated 14,000 new cases are diagnosed in the United States every year, leading to almost 4,300 deaths from the disease.

In this recording from the 21st International Congress of Cytology (ICC), Prof Mark Stoler shows evidence that the use of HPV DNA tests as the primary form of screening, followed by using p16/Ki-67 dual staining in triage can prove effective in identifying women who are at the highest risk of cervical cancer. This testing method gives actionable results that allows clinicians and health systems to prioritise resources for those who are in need of them.

Watch the recording

The post 21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy appeared first on Clinical Value of Diagnostics.

IPVC 2023 – How Peru broke down barriers to cervical cancer screening

Isabel Low — Tue, 14 May 2024 01:58:47 +0000

The World Health Organisation recommends HPV self-sampling to ease emotional and psychological barriers that prevent many women from pursuing screening, thus empowering women to choose the approach that works best for them. Following WHO’s recommendations, Dr Gino Venegas, while serving as Director of Cancer at the Ministry of Health in 2017, developed the National Cervical Cancer plan and implemented a HPV primary screening program. To help achieve a target of 70% screening coverage, Peru dedicated substantial resources to public education and setting up HPV testing facilities in primary care settings in both urban and rural areas.

In this recording from IPVC 2023, Dr Gino Venegas shares how Peru tackled cervical cancer by addressing numerous barriers to screening, such as lack of awareness, affordability challenges, and social stigma around HPV testing.

Watch the recording

The post IPVC 2023 – How Peru broke down barriers to cervical cancer screening appeared first on Clinical Value of Diagnostics.